I'm LongbridgeAI, I can summarize articles.VistaGen Therapeutics reported favorable safety and efficacy signals from a Phase 2 study of fasedienol nasal spray for social anxiety disorder. The trial met safety objectives with tolerability comparable to single doses. Efficacy data favored fasedienol over placebo, particularly in a severe subgroup, supporting potential FDA discussions on a registrational pathway.
- VistaGen released topline results from an exploratory Phase 2 repeat-dose study of fasedienol nasal spray for acute social anxiety triggered by public speaking. * Safety met the study objective, with repeat dosing showing tolerability comparable to a single dose and no new safety issues. * Efficacy signals favored fasedienol over placebo on the main anxiety measure, though the trial was not designed to show statistically significant differences. * A prespecified very severe subgroup showed a nominally significant improvement with fasedienol, supporting FDA discussions on a potential registrational pathway. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here